Keep us posted......

i disagree with tour 6 figure i don’t see it dropping below 7.50

Seems to me it’s going down a bit for a few weeks
7.84 seems to be about right.

RedHill Biopharma under pressure on $10M bought deal offering

Jan. 11, 2021 4:51 PM ETRedHill Biopharma Ltd. (RDHL)By: Khyathi Dalal, SA News Editor
RedHill Biopharma (NASDAQ:RDHL) entered into an underwriting agreement with H.C. Wainwright wherein the underwriter agreed to purchase on a firm commitment basis 1.28M ADSs at $7.84/ADS.
Underwriters granted 30-day option to purchase up to additional 191,326 ADSs at the public offering price.
Each ADS represents ten ordinary shares, par value NIS 0.01/share, of the company.
Gross proceeds expected to be ~$10M; net proceeds to be used for funding its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.
Offering is expected to close on on or about Jan. 14, 2021.

Thanks!

Another pearl in the article.......
Notably, apart from COVID-19, opaganib is being evaluated in a phase IIa study for treating advanced cholangiocarcinoma and in a phase II study for addressing prostate cancer.

Seems the market isn’t listening at the moment.

Love this part of the article........

Meanwhile, RedHill is set to start a phase II/III study on its second coronavirus candidate RHB-107 for addressing patients with symptomatic COVID-19 who do not require hospitalization. The FDA cleared an investigational new drug application for the study in November.

RedHill (RDHL) COVID-19 Drug Shows Promise in Mid-Stage Study

+1
Zacks Equity Research
Mon, January 4, 2021, 9:41 AM EST
RedHill Biopharma Ltd. RDHL announced encouraging preliminary top-line data from the exploratory phase II study in the United States, evaluating its oral drug candidate, opaganib (Yeliva), as a potential treatment for patients hospitalized with COVID-19 pneumonia. Data from the study showed that the opaganib is safe and demonstrated greater improvement in reducing oxygen requirement by end of treatment at day 14.

Moreover, primary and secondary efficacy outcomes correlated with clinical improvement as defined by the World Health Organization (WHO) ordinal scale. Full analysis of the data is expected to be reported in the coming weeks.

Please note that a global phase II/III study is evaluating opaganib in a similar patient population. Top-line data from the study is expected during the first quarter of 2021. Opaganib is both anti-inflammatory and antiviral, which is believed to treat the cause and the effects of COVID-19.

Shares of RedHill have surged 31.6% in the past year compared with the industry’s increase of 2.7%.
https://finance.yahoo.com/news/redhill-rdhl-covid-19-drug-144102738.html

You think we get Major PR Monday morning?
I methinks like Happy New Year!!!

looking forward to the. ews you posted hitting the Major Newspapers/Websites!!!

Just bought more @8.23

Just bought a few more shares

Amen brother!

How many more trading days left?

Methinks you are smart!

Small company from a small nation.... Gotta do it the hard way... earn it slow and sure!

Statement from the article....

“ Top-line data from the U.S. Phase 2 study of orally administered opaganib in patients with severe COVID-19, evaluating safety and potential efficacy signals, is expected later this month following the last patient’s last dose administered on November 26”

I hope he is that smart

GREAT NEWS!
Thanks midastouch017!!!

I’m so excited... been forwarding that link. Right on time, thanks!

WOW, great stuff ABC NEWS!

Thanks Midastiuch!

Seeking Alpha I believe!

Seeking Alpha I believe!

Well said...... three thousand die a date here in the US, a lotta people need some medicine now!

Are we expecting News this coming week?

I agree!!!!

Here’s the link to that article..... had so many problems trying to paste it before.
https://seekingalpha.com/article/4393522-redhill-slow-and-steady-climb-towards-biopharma-success

Financials
RedHill has a market cap of approximately $330 million and a cash balance of $51 million. The company has not done a secondary offering in the recent past. Its cash burn is approximately $50 million, although this is really guesswork on my part. It appears that RedHill's existing cash reserves will last for a year, so expect a dilution or at least some non-dilutive financing if the company can manage it.

Bottom line
RedHill looks like a somewhat boring, long-term, relatively risk-free, low-headache investment for investors. Its 52-week range is $3.51-10.82, and the stock is currently trading at $8.82. The pandemic has been both good and bad for RedHill, because while it has halted most of the company’s efforts, this was also when the company made a radical shift in its focus and concentrated on developing its own products. Even a 5-year chart of the company looks relatively stale and uninteresting. If you want to add some anchor to your portfolio, this is a benign-looking investment at current prices.

Market potential and value of the pipeline
Talicia’s US and global markets are estimated at $1.4 billion and $4.8 billion annually.

RHB-204 has an US market potential of $500 million in 2017. RHB-102 has a worldwide potential market of $650 million annually in gastroenteritis and gastritis. In IBS-D, 2019 US market potential was estimated at $980 million annually. For RHB-106, this is $560 million annually. RHB-104 for Crohn’s has a worldwide market estimate of over $12.8 billion. Now, if you add them together, you get a lot of billions. Even a 1% penetration assumption for all these drugs put together gives you over $150 million in annual sales for the company. That rate is immensely conservative in some respects, because Movantik itself is making nearly $100 million per year, annualized from actual revenues, for the company. Nor is RedHill any pushover when it comes to getting approvals. The company has successfully received approval for Talicia and has successfully marketed and sold Movantik despite the pandemic. It has also ably protected its assets with patents. If you read through the corporate presentation, you will see that the company has strong IP for every asset it owns.

Thus, there’s little doubt that RedHill will be able to successfully launch and commercialize most of its pipeline assets over the next 2-3 years, and will also be able to protect its IP. I intentionally gave a 3-year estimate, because these are mainly antibacterial drugs, and treatment duration and therefore trial duration is usually less. The longest-duration trial I think I saw was around a year. So, the company's only constraint is going to be funding, to which we will now arrive.

Aemcolo has not had a good year through no fault of RedHill. The pandemic hit right after the company acquired Aemcolo, severely impacting global travel, and Aemcolo is a drug FDA-approved for travelers’ diarrhea caused by noninvasive strains of E. coli in adults. Therefore, the drug didn’t sell, yet, but once travel restrictions are gone and a third of Americans begin going abroad (as they usually do every year), sales should pick up.

Meanwhile, the other thing that’s most important for RDHL and is going to start defining its future - instead of promoting legacy products or even licensing decent-looking small scale products from big pharma, the company is getting FDA approval for new formulations or delivery methods of existing products. Last year, it got approval for Talicia, a combination drug containing omeprazole magnesium, amoxicillin and rifabutin, indicated for the treatment of Helicobacter pylori infection in adults. H.pylori and its effect on peptic ulcers is a big deal; this discovery actually got the Nobel prize in 2005. There are approved antibacterial therapies, but they all suffer from antibacterial resistance. In fact, here’s a little diagram that illustrates this:

What was to come was two things - first, an excellent pair of deals with AstraZeneca (AZN) and privately held Cosmo, whereby RedHill acquired Movantik and Aemcolo respectively. Movantik is a revenue-generating naloxegol tablet FDA-approved for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Before it was acquired, it was generating around $96 million in annual revenue for AstraZeneca. This is, very roughly, the same amount RedHill will be paying to AstraZeneca as fees and royalties over the next few years. Meanwhile, despite the pandemic, which has badly affected everybody, including this company, it had revenues of $21 million in the November quarter - most of it, I assume, coming from Movantik.

SEEKING ALPHA
Article about RDHL
Summary

RedHill has a stable line of approved, marketed and pipeline products.
Its cash balance is a little low.
The company looks interesting for a long-term, low risk appetite investor.
RedHill Biopharma (RDHL) is an evolving specialty biopharma based out of Israel, with offices in the US. In earlier years, this small company was almost exclusively a promoter of other people’s legacy products - so it promoted and sold a number of low-grade products like Donnatal, Mystesi, EnteraGam and so on. Starting out in 2017, it used its sales force in the US to promote these products, made very little money, and discontinued the practice last year. However, it must have been a good learning experience for management and the sales team, making them ready for what was to come.

In parallel, RedHill is rapidly advancing its development program with opaganib in severe COVID-19 pneumonia; The U.S. Phase 2 study is fully enrolled with topline data expected within weeks, and a global Phase 2/3 study which is more than 50% enrolled, with topline data expected in Q1/2021 in support of potential emergency use applications

RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
RedHill Biopharma Ltd.
Thu, November 12, 2020, 7:00 AM EST·23 min read
Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020
--
Strong growth for Talicia® with approximately 300% quarter-over-quarter prescription growth and rapid expansion of the prescriber base; Talicia achieved national coverage for 167 million lives since launch, with additional coverage expected
--
Two consecutive quarters of Movantik® prescription (TRx) growth, reversing the trend of prescription decline prior to RedHill acquisition
--
Opaganib’s COVID-19 global Phase 2/3 study advancing rapidly with nearly 50% of patients enrolled and U.S. Phase 2 study over 90% enrolled; Initiated manufacturing ramp-up in preparation for potential emergency use applications as early as Q1/2021
--
Commencing Phase 3 study with RHB-204 for first-line treatment of pulmonary NTM infections
--
Cash balance of approximately $51 million as of September 30, 2020
--
Management to host webcast today, at 8:30 a.m. EST

We could use some good news, thanks for keeping us up to date my friend.

THANKS, I needed to hear this!

That REGN cocktail the President of the US just took this weekend got me scared as hell..... please tell me our product isn’t competing with it?

GREAT NEWS!